Hood River Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Hood River Capital Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-581,886	Closed	-$18.5M	–	150
2023 Q2	$18.5M	Buy	581,886 +9,010	+2%	+$277K	0.55%	66
2023 Q1	$14M	Sell	572,876 -350,762	-38%	-$10.3M	0.45%	69
2022 Q4	$29.1M	Buy	923,638 +27,066	+3%	+$764K	1.06%	40
2022 Q3	$25.3M	Buy	896,572 +473,322	+112%	+$14.1M	0.97%	39
2022 Q2	$11.2M	Buy	+423,250	New	+$12M	0.44%	73

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hood River Capital Management's CERE Position: Q3 2023 in Review

Hood River Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 581,886 shares — an estimated $18.5M sold.

Hood River Capital Management first reported a position in CERE in Q2 2022 and held it in 5 quarters. The position peaked at $29.1M in Q4 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

Hood River Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Hood River Capital Management sold 581,886 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $18.5M.
Hood River Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
Hood River Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $29.1M in Q4 2022.
119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Hood River Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.